Engineering Cancer Selective Virotherapies: Are the Pieces of the Puzzle Falling into Place?-Reference-Cited by-同舟云学术

Engineering Cancer Selective Virotherapies: Are the Pieces of the Puzzle Falling into Place?

Published:2022-11-04 Issue: Volume: Page:
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Swift Emma A.¹,Pollard Steven M.²,Parker Alan L.¹³^ORCID

Affiliation:

1. Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom

2. Centre for Regenerative Medicine, Institute for Regeneration and Repair & Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, United Kingdom

3. System Immunity University Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/hum.2022.178

Reference83 articles.

1. 1. High-dose AAV gene therapy deaths. Nat Biotechnol 2020;38(8):910.

2. The First Approved Gene Therapy Product for Cancer Ad-p53(Gendicine): 12 Years in the Clinic

3. Oncolytic Adenovirus in Cancer Immunotherapy

4. Adeno-associated virus (AAV) vectors in cancer gene therapy

5. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects;Frontiers in Immunology;2023-12-15

2. Channeling the Natural Properties of Sindbis Alphavirus for Targeted Tumor Therapy;International Journal of Molecular Sciences;2023-10-06

3. Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective;Viruses;2023-07-28